How does this impact ... I do all the work of picking the most attractive stocks. Analyst’s Disclosure: I/we have a beneficial long position in the shares of HIMS either through stock ownership ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

Bloomberg / Contributor / Getty Images Hims & Hers Health shares tumbled Thursday ... writers to use primary sources to support their work. These include white papers, government data, original ...

In the latest market close, Hims & Hers Health, Inc. (HIMS) reached $18.95, with a -1.86% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.

Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.